Pronova touts blockbuster, prepares IPO
Touting what it terms as a potential blockbuster among its products, Norway's Pronova BioPharma has outlined plans to sell about 106 million shares in an IPO prices at 23-29 nkr a share. The IPO for Pronova, which develops drugs based on Omega-3 fish oil, values the company at $1.25 billion to $1.57 billion.
"Pronova BioPharma is a highly profitable, fast-growing biopharma company and following strong progress in recent years, it is now an appropriate time to broaden our shareholder base," said Pronova chief executive Tomas Settevik.
- read the AFX report on Pronova's plans
ALSO: Targanta Therapeutics expects to raise up to $67.9 million from its IPO. Targanta was a 2007 Fierce 15 company. Report
Related Articles:
EU offers new ideas to spur biotech sector. Report
Tips for a successful biotech sector. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
